Document is current
Any future updates will be listed below
-
Authors
Magelssen, Morten
Rasmussen, Magnhild
Wallace, Sean
Førde, Reidun
- License Information
-
More Information
Article History
Received: 9 March 2021
Accepted: 27 April 2021
First Online: 4 May 2021
Declarations
:
: The study was evaluated and approved by the Data Protection Official at the Norwegian Centre for Research Data (ref. 320544); according to the Norwegian system, no further research ethics approval was required. Participants were informed about the project in writing and orally. Informed consent was obtained from all participants. The data do not contain information about individual patients. The research was carried out in accordance with all relevant guidelines and regulations.
: Not applicable.
: MM has received fees for lectures from Sanofi-Aventis and Roche. MR and SW are members of the national expert group on Spinraza treatment in spinal muscular atrophy (SMA) and work clinically with SMA patients. RF has no conflicts of interests.
